Targeting egfr for treatment of glioblastoma: Molecular basis to overcome resistance

Current Cancer Drug Targets

Volumn 12, Issue 3, 2012, Pages 197-209

  Taylor, T E ^a   Furnari, F B ^a,b,c   Cavenee, W K ^a,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Egfr targeted therapy; Epidermal growth factor receptor; Glioblastoma; Therapeutic resistance

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ABT 806; CANERTINIB; CARMUSTINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IRINOTECAN; LAPATINIB; LOMUSTINE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NIMOTUZUMAB; NITROSOUREA; PANITUMUMAB; PELITINIB; RINDOPEPIMUT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURGERY; CROSS RESISTANCE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; MULTIMODALITY CANCER THERAPY; NONHUMAN; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84857130051     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912799277557     Document Type: Review

References (113)

1. Furnari, F. B.; Fenton, T.; Bachoo, R. M.; Mukasa, A.; Stommel, J. M.; Stegh, A.; Hahn, W. C.; Ligon, K. L.; Louis, D. N.; Brennan, C.; Chin, L.; DePinho, R. A.; Cavenee, W. K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21 (21), 2683-2710.
2. Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455 (7216), 1061-1068.
3. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321 (5897), 1807-1812.
4. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5 (5), 341-354.
5. Karpel-Massler, G.; Schmidt, U.; Unterberg, A.; Halatsch, M. E. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol. Cancer Res. 2009, 7(7), 1000-1012.
6. Hasselbalch, B.; Lassen, U.; Poulsen, H. S.; Stockhausen, M. T. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling. Cancer Invest. 2010, 28 (8), 775-787.
7. Wells, A. EGF receptor. Int. J. Biochem. Cell Biol. 1999, 31 (6), 637-643.
8. Weinberg, R. A., The Biology of Cancer Garland Science: New York, 2007; p 796.
9. Gan, H. K.; Kaye, A. H.; Luwor, R. B. The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 2009, 16 (6), 748-754.
10. Frederick, L.; Wang, X. Y.; Eley, G.; James, C. D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000, 60 (5), 1383-1387.
11. Nishikawa, R.; Ji, X. D.; Harmon, R. C.; Lazar, C. S.; Gill, G. N.; Cavenee, W. K.; Huang, H. J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 1994, 91 (16), 7727- 7731.
12. Schmidt, M. H.; Furnari, F. B.; Cavenee, W. K.; Bogler, O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (11), 6505-6510.
13. Huang, H. S.; Nagane, M.; Klingbeil, C. K.; Lin, H.; Nishikawa, R.; Ji, X. D.; Huang, C. M.; Gill, G. N.; Wiley, H. S.; Cavenee, W. K. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 1997, 272 (5), 2927-2935.
14. Nagane, M.; Lin, H.; Cavenee, W. K.; Huang, H. J. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett. 2001, 162 Suppl, S17-S21.
15. Raizer, J. J.; Abrey, L. E.; Lassman, A. B.; Chang, S. M.; Lamborn, K. R.; Kuhn, J. G.; Yung, W. K.; Gilbert, M. R.; Aldape, K. A.; Wen, P. Y.; Fine, H. A.; Mehta, M.; Deangelis, L. M.; Lieberman, F.; Cloughesy, T. F.; Robins, H. I.; Dancey, J.; Prados, M. D. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro. Oncol. 2010, 12 (1), 95-103.
16. Rich, J. N.; Rasheed, B. K.; Yan, H. EGFR mutations and sensitivity to gefitinib. N. Engl. J. Med. 2004, 351 (12), 1260-1261; author reply 1260-1261.
17. Ji, H.; Sharpless, N. E.; Wong, K. K. EGFR targeted therapy: view from biological standpoint. Cell Cycle 2006, 5 (18), 2072-2076.
18. Wen, P. Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359 (5), 492-507.
19. Ladha, J.; Donakonda, S.; Agrawal, S.; Thota, B.; Srividya, M. R.; Sridevi, S.; Arivazhagan, A.; Thennarasu, K.; Balasubramaniam, A.; Chandramouli, B. A.; Hegde, A. S.; Kondaiah, P.; Somasundaram, K.; Santosh, V.; Rao, S. M. Glioblastoma-specific protein interaction network identifies PP1A and CSK21 as connecting molecules between cell cycle-associated genes. Cancer Res. 2010, 70 (16), 6437-6447.
20. Scheithauer, B. W.; Erdogan, S.; Rodriguez, F. J.; Burger, P. C.; Woodruff, J. M.; Kros, J. M.; Gokden, M.; Spinner, R. J. Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases. Am. J. Surg. Pathol. 2009, 33 (3), 325-338.
21. Maher, E. A.; Furnari, F. B.; Bachoo, R. M.; Rowitch, D. H.; Louis, D. N.; Cavenee, W. K.; DePinho, R. A. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001, 15 (11), 1311-1333.
22. Jones, T. S.; Holland, E. C. Molecular pathogenesis of malignant glial tumors. Toxicol. Pathol. 2011, 39 (1), 158-166.
23. Ohgaki, H.; Dessen, P.; Jourde, B.; Horstmann, S.; Nishikawa, T.; Di Patre, P. L.; Burkhard, C.; Schuler, D.; Probst-Hensch, N. M.; Maiorka, P. C.; Baeza, N.; Pisani, P.; Yonekawa, Y.; Yasargil, M. G.; Lutolf, U. M.; Kleihues, P. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004, 64 (19), 6892-6899.
24. Watanabe, K.; Tachibana, O.; Sata, K.; Yonekawa, Y.; Kleihues, P.; Ohgaki, H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996, 6(3), 217-223; discussion 223-214.
25. Yan, H.; Parsons, D. W.; Jin, G.; McLendon, R.; Rasheed, B. A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G. J.; Friedman, H.; Friedman, A.; Reardon, D.; Herndon, J.; Kinzler, K. W.; Velculescu, V. E.; Vogelstein, B.; Bigner, D. D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360 (8), 765-773.
26. Tortora, G.; Bianco, R.; Daniele, G.; Ciardiello, F.; McCubrey, J. A.; Ricciardi, M. R.; Ciuffreda, L.; Cognetti, F.; Tafuri, A.; Milella, M. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist. Updat. 2007, 10 (3), 81-100.
27. Shinojima, N.; Tada, K.; Shiraishi, S.; Kamiryo, T.; Kochi, M.; Nakamura, H.; Makino, K.; Saya, H.; Hirano, H.; Kuratsu, J.; Oka, K.; Ishimaru, Y.; Ushio, Y. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003, 63 (20), 6962-6970.
28. Nagane, M.; Coufal, F.; Lin, H.; Bogler, O.; Cavenee, W. K.; Huang, H. J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996, 56 (21), 5079-5086.
29. Moscatello, D. K.; Holgado-Madruga, M.; Emlet, D. R.; Montgomery, R. B.; Wong, A. J. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. 1998, 273 (1), 200-206.
30. Lal, A.; Glazer, C. A.; Martinson, H. M.; Friedman, H. S.; Archer, G. E.; Sampson, J. H.; Riggins, G. J. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002, 62 (12), 3335-3339.
31. Mishima, K.; Johns, T. G.; Luwor, R. B.; Scott, A. M.; Stockert, E.; Jungbluth, A. A.; Ji, X. D.; Suvarna, P.; Voland, J. R.; Old, L. J.; Huang, H. J.; Cavenee, W. K. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 2001, 61 (14), 5349-5354.
32. Silvani, A.; Gaviani, P.; Lamperti, E. A.; Eoli, M.; Falcone, C.; Dimeco, F.; Milanesi, I. M.; Erbetta, A.; Boiardi, A.; Fariselli, L.; Salmaggi, A. Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. J. Neurooncol. 2009, 94 (1), 57-62.
33. Grossman, S. A.; Batara, J. F. Current management of glioblastoma multiforme. Semin. Oncol. 2004, 31 (5), 635-644.
34. La Rocca, R. V.; Mehdorn, H. M. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr. Med. Res. Opin. 2009, 25 (1), 149-160.
35. Walker, M. D. The contemporary role of chemotherapy in the treatment of malignant brain tumor. Clin. Neurosurg. 1978, 25, 388-396.
36. Walker, M. D.; Green, S. B.; Byar, D. P.; Alexander, E.; Batzdorf, U.; Brooks, W. H.; Hunt, W. E.; MacCarty, C. S.; Mahaley, M. S.; Mealey, J.; Owens, G.; Ransohoff, J.; Robertson, J. T.; Shapiro, W. R.; Smith, K. R.; Wilson, C. B.; Strike, T. A. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 1980, 303 (23), 1323-1329.
37. Agarwala, S. S.; Kirkwood, J. M. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000, 5 (2), 144-151.
38. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352 (10), 987-996.
39. Slamon, D.; Pegram, M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin. Oncol. 2001, 28 (1 Suppl 3), 13-19.
40. Norden, A. D.; Drappatz, J.; Wen, P. Y. Antiangiogenic therapy in malignant gliomas. Curr. Opin. Oncol. 2008, 20 (6), 652-661.
41. Norden, A. D.; Drappatz, J.; Wen, P. Y. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008, 7 (12), 1152-1160.
42. Mischel, P. S.; Cloughesy, T. F. Targeted molecular therapy of GBM. Brain Pathol. 2003, 13 (1), 52-61.
43. Wikstrand, C. J.; Hale, L. P.; Batra, S. K.; Hill, M. L.; Humphrey, P. A.; Kurpad, S. N.; McLendon, R. E.; Moscatello, D.; Pegram, C.N.; Reist, C. J.; Traweek, S. T.; Wong, A. J.; Zalutsky, M. R.; Bigner, D. D. Monoclonal antibodies against EGFRvIII are tumorspecific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995, 55 (14), 3140-3148.
44. Johnson, L. A.; Sampson, J. H. Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr. Neurol. Neurosci. Rep. 2010, 10 (4), 259-266.
45. Weiner, L. M.; Surana, R.; Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10 (5), 317-327.
46. Ehrlich, P., Collected Studies on Immunity. J. Wiley & Sons: New York, 1906.
47. Rivera, F.; Vega-Villegas, M. E.; Lopez-Brea, M. F. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008, 19 (2), 99-113.
48. Eller, J. L.; Longo, S. L.; Kyle, M. M.; Bassano, D.; Hicklin, D. J.; Canute, G. W. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery. 2005, 56(1), 155-162; discussion 162.
49. Eller, J. L.; Longo, S. L.; Hicklin, D. J.; Canute, G. W. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery. 2002, 51(4), 1005-1013; discussion 1013-1004.
50. Combs, S. E.; Heeger, S.; Haselmann, R.; Edler, L.; Debus, J.; Schulz-Ertner, D. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-phase I/II trial: study protocol. BMC Cancer 2006, 6, 133.
51. Cho, J.; Pastorino, S.; Zeng, Q.; Xu, X.; Johnson, W.; Vandenberg, S.; Verhaak, R.; Cherniack, A. D.; Watanabe, H.; Dutt, A.; Kwon, J.; Chao, Y. S.; Onofrio, R. C.; Chiang, D.; Yuza, Y.; Kesari, S.; Meyerson, M. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011, 71 (24), 1-10.
52. Emrich, J. G.; Brady, L. W.; Quang, T. S.; Class, R.; Miyamoto, C.; Black, P.; Rodeck, U. Radioiodinated (I-125) monoclonal antibody 25 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am. J. Clin. Oncol. 2002, 25 (6), 541-546.
53. Quang, T. S.; Brady, L. W. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58 (3), 972-975.
54. Li, L.; Quang, T. S.; Gracely, E. J.; Kim, J. H.; Emrich, J. G.; Yaeger, T. E.; Jenrette, J. M.; Cohen, S. C.; Black, P.; Brady, L. W. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J. Neurosurg. 2010, 113 (2), 192-198.
55. Liu, T. F.; Hall, P. D.; Cohen, K. A.; Willingham, M. C.; Cai, J.; Thorburn, A.; Frankel, A. E. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin. Cancer Res. 2005, 11 (1), 329-334.
56. Gan, H. K.; Lappas, M.; Cao, D. X.; Cvrljevdic, A.; Scott, A. M.; Johns, T. G. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. J. Cell Mol. Med. 2009, 13 (9B), 3993-4001.
57. Luwor, R. B.; Johns, T. G.; Murone, C.; Huang, H. J.; Cavenee, W. K.; Ritter, G.; Old, L. J.; Burgess, A. W.; Scott, A. M. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res. 2001, 61 (14), 5355-5361.
58. Scott, A. M.; Lee, F. T.; Tebbutt, N.; Herbertson, R.; Gill, S. S.; Liu, Z.; Skrinos, E.; Murone, C.; Saunder, T. H.; Chappell, B.; Papenfuss, A. T.; Poon, A. M.; Hopkins, W.; Smyth, F. E.; MacGregor, D.; Cher, L. M.; Jungbluth, A. A.; Ritter, G.; Brechbiel, M. W.; Murphy, R.; Burgess, A. W.; Hoffman, E. W.; Johns, T. G.; Old, L. J. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (10), 4071-4076.
59. Moscatello, D. K.; Ramirez, G.; Wong, A. J. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res. 1997, 57 (8), 1419-1424.
60. Kanaly, C. W.; Ding, D.; Heimberger, A. B.; Sampson, J. H. Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg. Clin. N. Am. 2010, 21 (1), 95-109.
61. Yamanaka, R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg. Rev. 2009, 32(3), 265-273; discussion 273.
62. Heimberger, A. B.; Sampson, J. H. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert. Opin. Biol. Ther. 2009, 9 (8), 1087-1098.
63. Sampson, J. H.; Archer, G. E.; Mitchell, D. A.; Heimberger, A. B.; Herndon, J. E., 2nd; Lally-Goss, D.; McGehee-Norman, S.; Paolino, A.; Reardon, D. A.; Friedman, A. H.; Friedman, H. S.; Bigner, D. D. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol. Cancer Ther. 2009, 8 (10), 2773-2779.
64. Kohno, M.; Horibe, T.; Haramoto, M.; Yano, Y.; Ohara, K.; Nakajima, O.; Matsuzaki, K.; Kawakami, K. A novel hybrid peptide targeting EGFR-expressing cancers. Eur. J. Cancer 2011, 47 (5), 773-783.
65. Tada, N.; Horibe, T.; Haramoto, M.; Ohara, K.; Kohno, M.; Kawakami, K. A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity. Biochem. Biophys. Res. Commun. 2011, 407 (2), 383-388.
66. Sampson, J. H.; Heimberger, A. B.; Archer, G. E.; Aldape, K. D.; Friedman, A. H.; Friedman, H. S.; Gilbert, M. R.; Herndon, J. E.; McLendon, R. E.; Mitchell, D. A.; Reardon, D. A.; Sawaya, R.; Schmittling, R. J.; Shi, W.; Vredenburgh, J. J.; Bigner, D. D. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newlydiagnosed glioblastoma. J. Clin. Oncol. 2010, 28 (31), 4722-4729.
67. Halatsch, M. E.; Gehrke, E. E.; Vougioukas, V. I.; Botefur, I. C.; Efferth, T.; Gebhart, E.; Domhof, S.; Schmidt, U.; Buchfelder, M. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J. Neurosurg. 2004, 100 (3), 523-533.
68. Moyer, J. D.; Barbacci, E. G.; Iwata, K. K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrio, C.; Doty, J.; Morin, M. J.; Moyer, M. P.; Neveu, M.; Pollack, V. A.; Pustilnik, L. R.; Reynolds, M. M.; Sloan, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57 (21), 4838-4848.
69. Quatrale, A. E.; Porcelli, L.; Silvestris, N.; Colucci, G.; Angelo, A.; Azzariti, A. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front. Biosci. 2011, 16, 1962-1972.
70. Mellinghoff, I. K.; Wang, M. Y.; Vivanco, I.; Haas-Kogan, D. A.; Zhu, S.; Dia, E. Q.; Lu, K. V.; Yoshimoto, K.; Huang, J. H.; Chute, D. J.; Riggs, B. L.; Horvath, S.; Liau, L. M.; Cavenee, W. K.; Rao, P. N.; Beroukhim, R.; Peck, T. C.; Lee, J. C.; Sellers, W. R.; Stokoe, D.; Prados, M.; Cloughesy, T. F.; Sawyers, C. L.; Mischel, P. S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353 (19), 2012-2024.
71. Knight, L. A.; Di Nicolantonio, F.; Whitehouse, P.; Mercer, S.; Sharma, S.; Glaysher, S.; Johnson, P.; Cree, I. A. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 2004, 4, 83.
72. Hegi, M. E.; Diserens, A. C.; Bady, P.; Kamoshima, Y.; Kouwenhoven, M. C.; Delorenzi, M.; Lambiv, W. L.; Hamou, M. F.; Matter, M. S.; Koch, A.; Heppner, F. L.; Yonekawa, Y.; Merlo, A.; Frei, K.; Mariani, L.; Hofer, S. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Mol. Cancer Ther. 2011, 10 (6), 1102-1112.
73. Learn, C. A.; Hartzell, T. L.; Wikstrand, C. J.; Archer, G. E.; Rich, J. N.; Friedman, A. H.; Friedman, H. S.; Bigner, D. D.; Sampson, J. H. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin. Cancer Res. 2004, 10 (9), 3216-3224.
74. Rich, J. N.; Bigner, D. D. Development of novel targeted therapies in the treatment of malignant glioma. Nat. Rev. Drug Discov. 2004, 3 (5), 430-446.
75. Sarkaria, J. N.; Yang, L.; Grogan, P. T.; Kitange, G. J.; Carlson, B. L.; Schroeder, M. A.; Galanis, E.; Giannini, C.; Wu, W.; Dinca, E. B.; James, C. D. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol. Cancer Ther. 2007, 6 (3), 1167-1174.
76. Castanotto, D.; Rossi, J. J. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009, 457 (7228), 426-433.
77. Sowery, R. D.; Hadaschik, B. A.; So, A. I.; Zoubeidi, A.; Fazli, L.; Hurtado-Coll, A.; Gleave, M. E. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 2008, 102 (3), 389-397.
78. Shir, A.; Levitzki, A. Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR. Nat. Biotechnol. 2002, 20 (9), 895-900.
79. Kang, C. S.; Zhang, Z. Y.; Jia, Z. F.; Wang, G. X.; Qiu, M. Z.; Zhou, H. X.; Yu, S. Z.; Chang, J.; Jiang, H.; Pu, P. Y. Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther. 2006, 13 (5), 530-538.
80. Kim, C.; Shah, B. P.; Subramaniam, P.; Lee, K. B. Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer Drugs Mol. Pharm. 2011, 8 (5), 1955-1961.
81. Engelman, J. A.; Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 2008, 18 (1), 73-79.
82. Wykosky, J.; Mukasa, A.; Furnari, F.; Cavenee, W. K. Escape from targeted inhibition: the dark side of kinase inhibitor therapy. Cell Cycle 2010, 9 (9), 1661-1662.
83. Engelman, J. A.; Janne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung Cancer Clin. Cancer Res. 2008, 14 (10), 2895-2899.
84. Inda, M. M.; Bonavia, R.; Mukasa, A.; Narita, Y.; Sah, D. W.; Vandenberg, S.; Brennan, C.; Johns, T. G.; Bachoo, R.; Hadwiger, P.; Tan, P.; Depinho, R. A.; Cavenee, W.; Furnari, F. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010, 24 (16), 1731-1745.
85. Krakstad, C.; Chekenya, M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol. Cancer 2010, 9, 135.
86. Nagane, M.; Levitzki, A.; Gazit, A.; Cavenee, W. K.; Huang, H. J. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (10), 5724-5729.
87. Mukasa, A.; Wykosky, J.; Ligon, K. L.; Chin, L.; Cavenee, W. K.; Furnari, F. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (6), 2616-2621.
88. Weihua, Z.; Tsan, R.; Huang, W. C.; Wu, Q.; Chiu, C. H.; Fidler, I. J.; Hung, M. C. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13 (5), 385-393.
89. Pommier, Y.; Sordet, O.; Antony, S.; Hayward, R. L.; Kohn, K. W. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004, 23 (16), 2934-2949.
90. Jiang, Z.; Zheng, X.; Rich, K. M. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J. Neurochem. 2003, 84 (2), 273-281.
91. Johns, T. G.; Perera, R. M.; Vernes, S. C.; Vitali, A. A.; Cao, D. X.; Cavenee, W. K.; Scott, A. M.; Furnari, F. B. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin. Cancer Res. 2007, 13 (6), 1911-1925.
92. Yonesaka, K.; Zejnullahu, K.; Okamoto, I.; Satoh, T.; Cappuzzo, F.; Souglakos, J.; Ercan, D.; Rogers, A.; Roncalli, M.; Takeda, M.; Fujisaka, Y.; Philips, J.; Shimizu, T.; Maenishi, O.; Cho, Y.; Sun, J.; Destro, A.; Taira, K.; Takeda, K.; Okabe, T.; Swanson, J.; Itoh, H.; Takada, M.; Lifshits, E.; Okuno, K.; Engelman, J. A.; Shivdasani, R. A.; Nishio, K.; Fukuoka, M.; Varella-Garcia, M.; Nakagawa, K.; Janne, P. A. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 2011, 3(99), 99ra86.
93. Stommel, J. M.; Kimmelman, A. C.; Ying, H.; Nabioullin, R.; Ponugoti, A. H.; Wiedemeyer, R.; Stegh, A. H.; Bradner, J. E.; Ligon, K. L.; Brennan, C.; Chin, L.; DePinho, R. A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007, 318 (5848), 287-290.
94. Hu, J.; Jo, M.; Cavenee, W. K.; Furnari, F.; VandenBerg, S. R.; Gonias, S. L. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (38), 15984-15989.
95. Sharma, S. V.; Lee, D. Y.; Li, B.; Quinlan, M. P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.; Zou, L.; Fischbach, M. A.; Wong, K. K.; Brandstetter, K.; Wittner, B.; Ramaswamy, S.; Classon, M.; Settleman, J. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141 (1), 69-80.
96. Snuderl, M.; Fazlollahi, L.; Le, L. P.; Nitta, M.; Zhelyazkova, B. H.; Davidson, C. J.; Akhavanfard, S.; Cahill, D. P.; Aldape, K. D.; Betensky, R. A.; Louis, D. N.; Iafrate, A. J. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011, 20 (6), 810-817.
97. Huang, P. H.; Mukasa, A.; Bonavia, R.; Flynn, R. A.; Brewer, Z. E.; Cavenee, W. K.; Furnari, F. B.; White, F. M. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (31), 12867-12872.
98. Jun, H. J.; Acquaviva, J.; Chi, D.; Lessard, J.; Zhu, H.; Woolfenden, S.; Bronson, R. T.; Pfannl, R.; White, F.; Housman, D. E.; Iyer, L.; Whittaker, C. A.; Boskovitz, A.; Raval, A.; Charest, A. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 2011, 1-12.
99. Eimer, S.; Belaud-Rotureau, M. A.; Airiau, K.; Jeanneteau, M.; Laharanne, E.; Veron, N.; Vital, A.; Loiseau, H.; Merlio, J. P.; Belloc, F. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol. Ther. 2011, 11 (12), 1017-1027.
100. Fan, Q. W.; Weiss, W. A. Autophagy and Akt promote survival in glioma. Autophagy. 2011, 7 (5), 536-538.
101. Fan, Q. W.; Cheng, C.; Hackett, C.; Feldman, M.; Houseman, B. T.; Nicolaides, T.; Haas-Kogan, D.; James, C. D.; Oakes, S. A.; Debnath, J.; Shokat, K. M.; Weiss, W. A. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci. Signal. 2010, 3(147), ra81.
102. Pu, Y. S.; Hour, T. C.; Chuang, S. E.; Cheng, A. L.; Lai, M. K.; Kuo, M. L. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 2004, 60 (2), 120-129.
103. Jin, X.; Yin, J.; Kim, S. H.; Sohn, Y. W.; Beck, S.; Lim, Y. C.; Nam, D. H.; Choi, Y. J.; Kim, H. EGFR-AKT-Smad Signaling Promotes Formation of Glioma Stem-like Cells and Tumor Angiogenesis by ID3-Driven Cytokine Induction. Cancer Res. 2011, 71 (22), 7125-7134.
104. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; Rich, J. N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444 (7120), 756-760.
105. Sanchez-Garcia, I.; Vicente-Duenas, C.; Cobaleda, C. The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice? Bioessays 2007, 29 (12), 1269-1280.
106. Gilbert, L. A.; Hemann, M. T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143 (3), 355-366.
107. Gong, X.; Schwartz, P. H.; Linskey, M. E.; Bota, D. A. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology 2011, 76 (13), 1126-1134.
108. Guryanova, O. A.; Wu, Q.; Cheng, L.; Lathia, J. D.; Huang, Z.; Yang, J.; MacSwords, J.; Eyler, C. E.; McLendon, R. E.; Heddleston, J. M.; Shou, W.; Hambardzumyan, D.; Lee, J.; Hjelmeland, A. B.; Sloan, A. E.; Bredel, M.; Stark, G. R.; Rich, J. N.; Bao, S. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011, 19 (4), 498-511.
109. Heimberger, A. B.; Kong, L. Y.; Abou-Ghazal, M.; Reina-Ortiz, C.; Yang, D. S.; Wei, J.; Qiao, W.; Schmittling, R. J.; Archer, G. E.; Sampson, J. H.; Hiraoka, N.; Priebe, W.; Fuller, G. N.; Sawaya, R. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin. Neurosurg. 2009, 56, 98-106.
110. Fecci, P. E.; Mitchell, D. A.; Whitesides, J. F.; Xie, W.; Friedman, A. H.; Archer, G. E.; Herndon, J. E.; Bigner, D. D.; Dranoff, G.; Sampson, J. H. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006, 66 (6), 3294-3302.
111. Iwamaru, A.; Szymanski, S.; Iwado, E.; Aoki, H.; Yokoyama, T.; Fokt, I.; Hess, K.; Conrad, C.; Madden, T.; Sawaya, R.; Kondo, S.; Priebe, W.; Kondo, Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007, 26 (17), 2435-2444.
112. Dalton, W. S. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist. Updat. 1999, 2 (5), 285-288.
113. Yao, Z.; Fenoglio, S.; Gao, D. C.; Camiolo, M.; Stiles, B.; Lindsted, T.; Schlederer, M.; Johns, C.; Altorki, N.; Mittal, V.; Kenner, L.; Sordella, R. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung Cancer Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (35), 15535-15540.